Alfonso Pérez

4.8k total citations · 2 hit papers
69 papers, 3.7k citations indexed

About

Alfonso Pérez is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Alfonso Pérez has authored 69 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Endocrinology, Diabetes and Metabolism, 23 papers in Cardiology and Cardiovascular Medicine and 14 papers in Molecular Biology. Recurrent topics in Alfonso Pérez's work include Diabetes Treatment and Management (20 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (13 papers) and Computational Drug Discovery Methods (12 papers). Alfonso Pérez is often cited by papers focused on Diabetes Treatment and Management (20 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (13 papers) and Computational Drug Discovery Methods (12 papers). Alfonso Pérez collaborates with scholars based in United States, Spain and Japan. Alfonso Pérez's co-authors include Ralph B. D’Agostino, Steven M. Haffner, Stuart Kupfer, Theodore Mazzone, Steven B. Feinstein, George T. Kondos, Michael H. Davidson, George L. Bakris, Steven E. Nissen and Kathy Wolski and has published in prestigious journals such as JAMA, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Alfonso Pérez

69 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

2008 664 citations Steven E. Nissen, Stephen J. Nicholls et al. JAMA profile →
Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes

2006 532 citations Alfonso Pérez et al. JAMA profile →

Peers

Countries citing papers authored by Alfonso Pérez

Since Specialization

Citations

This map shows the geographic impact of Alfonso Pérez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfonso Pérez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfonso Pérez more than expected).

Fields of papers citing papers by Alfonso Pérez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfonso Pérez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfonso Pérez. The network helps show where Alfonso Pérez may publish in the future.

Co-authorship network of co-authors of Alfonso Pérez

This figure shows the co-authorship network connecting the top 25 collaborators of Alfonso Pérez. A scholar is included among the top collaborators of Alfonso Pérez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfonso Pérez. Alfonso Pérez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Monastrol suppresses invasion and metastasis in human colorectal cancer cells by targeting fascin independent of kinesin-Eg5 pathway 2024 ·Biomedicine & Pharmacotherapy ·(unknown), Silvia Montoro‐García, Ángel Bernabé‐García, (unknown), (unknown), (unknown), Irene Luque, Tuula Salo, Alfonso Pérez, (unknown), María L. Cayuela, Ginés Luengo‐Gil, Enrico Luchinat, (unknown), (unknown), Francisco José Nicolás, Pablo Conesa‐Zamora	1
2	2D finger-printing and molecular docking studies identified potent mosquito repellents targeting odorant binding protein 1 2023 ·Insect Biochemistry and Molecular Biology ·(unknown), Alfonso Pérez, Katerina E. Tsitsanou, K.V. Dileep, Αntonios Michaelakis, Dimitrios Papachristos, Horacio Pérez‐Sánchez, S.E. Zographos	4
3	Fishing the Targets of Bioactive Compounds from Psidium guajava L. Leaves in the Context of Diabetes 2023 ·International Journal of Molecular Sciences ·Elixabet Díaz‐de‐Cerio, (unknown), Alfonso Pérez, (unknown), José Antonio Gabaldón, Vito Verardo, Antonio Segura‐Carretero, Horacio Pérez‐Sánchez	6
4	Ten‐year observational follow‐up of PROactive : a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes 2015 ·Diabetes Obesity and Metabolism ·E Erdmann, Simon Harding, Hung‐Ming Lam, Alfonso Pérez	67
5	Latest QSAR study of adenosine A $$_{\mathrm{2B}}$$ 2 B receptor affinity of xanthines and deazaxanthines 2015 ·Molecular Diversity ·Alfonso Pérez, Virginia Rivero‐Buceta, (unknown), Sanjay Kumar, Horacio Pérez‐Sánchez, Marta Teijeira	5
6	Topological structural alerts modulations of mammalian cell mutagenicity for halogenated derivatives 2013 ·SAR and QSAR in environmental research ·Alfonso Pérez, (unknown), Aliuska Morales Helguera, Fernanda Borges, Robert D. Combes	5
7	Biomarkers of oxidative stress in patients with wet age related macular degeneration 2012 ·The journal of nutrition health & aging ·Pilar Zafrilla, M. Losada, Alfonso Pérez, (unknown), Juana Mulero	25
8	Topological sub-structural molecular design approach: Radical scavenging activity 2012 ·European Journal of Medicinal Chemistry ·Alfonso Pérez, Aliuska Morales Helguera, (unknown), Pilar Zafrilla	13
9	Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients 2011 ·Journal of the American College of Cardiology ·Stephen J. Nicholls, E. Murat Tuzcu, Kathy Wolski, Özgür Bayturan, Andrea Lavoie, Kiyoko Uno, Stuart Kupfer, Alfonso Pérez, Richard W. Nesto, Steven E. Nissen	82
10	Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring 2011 ·Journal of Clinical Hypertension ·Domenic Sica, William B. White, Michael A. Weber, George L. Bakris, Alfonso Pérez, Charlie Cao, (unknown), Stuart Kupfer	91
11	QSAR models to predict mutagenicity of acrylates, methacrylates and α,β-unsaturated carbonyl compounds 2010 ·Dental Materials ·Alfonso Pérez, Aliuska Morales Helguera, (unknown), M. Natália D. S. Cordeiro	22
12	Comparison of Pioglitazone vs Glyburide in Early Heart Failure: Insights From a Randomized Controlled Study of Patients With Type 2 Diabetes and Mild Cardiac Disease 2010 ·Congestive Heart Failure ·Thomas D. Giles, Uri Elkayam, Mondira Bhattacharya, Alfonso Pérez, Alan B. Miller	25
13	A topological substructural molecular design approach for predicting mutagenesis end-points of α, β-unsaturated carbonyl compounds 2009 ·Toxicology ·Alfonso Pérez, Aliuska Morales Helguera, (unknown), M. Natália D. S. Cordeiro, (unknown)	27
14	Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes breakdown → 2008 ·JAMA ·Steven E. Nissen, Stephen J. Nicholls, Kathy Wolski, Richard W. Nesto, Stuart Kupfer, Alfonso Pérez, Horacio O. Jure, Robert De Larochellière, Cezar Staniloae, Kreton Mavromatis, Jacqueline Saw, Bo Hu, A. Michael Lincoff, E. Murat Tuzcu, (unknown)	664
15	Halogenated derivatives QSAR model using spectral moments to predict haloacetic acids (HAA) mutagenicity 2008 ·Bioorganic & Medicinal Chemistry ·Alfonso Pérez, Maykel Pérez González, (unknown)	14
16	Characteristics of physical activity habits in type 2 diabetes patients in Spain 2008 ·Avances en Diabetología ·Serafín Murillo, (unknown), Alfonso Pérez, Anna Espinal, A. Enrique Caballero	1
17	Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy 2006 ·Diabetes Obesity and Metabolism ·Paulos Berhanu, Alfonso Pérez, Shawn Yu	39
18	Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double‐blind, multicentre, randomized study 2005 ·Diabetes Obesity and Metabolism ·Jaime A. Davidson, Alfonso Pérez, (unknown), (unknown)	30
19	Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone 2004 ·Diabetes Obesity and Metabolism ·Rukmini Rajagopalan, Shrividya Iyer, Alfonso Pérez	17
20	Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus 2004 ·Drugs & Aging ·Rukmini Rajagopalan, Alfonso Pérez, Zhan Ye, Mehmood Khan, Frederick T. Murray	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact